PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brcKargerHomeAlertsResources
 
Breast Care (Basel). 2009 February; 4(1): 22–29.
Published online 2009 February 20. doi:  10.1159/000200980
PMCID: PMC2942013

Language: English | German

Isoflavones - Mechanism of Action and Impact on Breast Cancer Risk

Summary

Isoflavones are plant-derived substances with weak es-trogenic effects. Asian populations are high consumers of soy products which are rich in isoflavones. The lower breast cancer incidence in Asian women compared with Western women has been associated with the possibility of a preventive isoflavone effect on cancer risk. The aim of this review is to give an overview of current research data on the influence of isoflavones on the risk of primary breast cancer development as well as the risk of recurrence in breast cancer patients. Despite inconsistencies in the available data, an inverse correlation between isoflavone intake and risk of breast cancer is likely. However, a negative impact on breast cancer disease, especially on hormone receptor-positive tumors, cannot be excluded at present.

Key Words: Phytoestrogens, Isoflavones, Breast cancer, Nutrition, Prevention, Risk factors

Zusammenfassung

Isoflavone sind Substanzen pflanzlichen Ursprungs, welche schwach östrogene Wirkung aufweisen. Die Bevölkerung Asiens zeichnet sich durch einen hohen Konsum an isoflavonreicher Sojakost aus. Die im Vergleich zu westlichen Frauen niedrigere Brustkrebsinzidenz bei Asiatinnen wurde mit der Möglichkeit einer präventiven Isoflavonwirkung auf das Krebsrisiko in Verbindung gebracht. Die vorliegende Arbeit gibt einen Überblick über aktuelle Studien sowohl zum Einfluss von Isoflavonen auf das Risiko der Brustkrebsentstehung als auch auf das Rezidivrisiko nach Brustkrebserkrankung. Trotz inkonsistenter Studienlage scheint zwischen Isoflavonaufnahme und Brustkrebsrisiko ein inverser Effekt zu bestehen. Nach Brustkrebserkrankung kann ein negativer Effekt, insbesondere bei hormonsensitiven Tumoren, nicht ausgeschlossen werden.

Introduction

The annual breast cancer incidence rates in Western European countries and in the USA range from about 80 to 100 per 100,000 women. In contrast, the incidence rate in Japan, a country with a comparable level of industrialization, is with 33/100,000 only about a third of that in the USA [1]. Migration studies show a shift from low to higher incidence rates among Asian-American women within one generation after migration, and suggest environmental influences to be responsible for the observed difference in breast cancer risk. The consumption of soy food, which is rich in biologically active phy-toestrogens, is traditionally high in Japan. Consequently, phy-toestrogens have been connected with the low breast cancer incidence rates in the high-soy-consuming Asian populations. The most common class of phytoestrogens in soy products are isoflavones. Therefore, almost all studies elucidated the role of soy products and isoflavones, respectively. Of further interest, especially in Western populations, is the safety of isoflavone intake among breast cancer patients [2]. The alleged effects of isoflavones on reducing menopausal vasomotor symptoms make them a commonly used alternative therapy option instead of hormone therapy with estrogens or estrogen/progestin combinations. A meta-analysis of 6 trials on the influence of soy isoflavones on the number of hot flashes per day revealed a weak beneficial effect for soy isoflavones compared with placebo (mean difference in the number of hot flashes per day −1.22, 95% confidence interval (CI) = −2.02 to −0.42) [3]. However, the findings of these trials were rather contradictory and the study assessment of poor quality. A further meta-analysis of another 6 trials compared isoflavone extracts from red clover with placebo and showed a weak difference of only −0.44, 95% CI = −0.47 to 0.58 [3]. This beneficial trend could be confirmed by 2 current randomized, double-blinded placebo-controlled trials (doses of dietary isoflavone intake 40-100 mg/day for 12 weeks to 12 months) [4, 5].

Classification, Structure, and Metabolism of Isoflavones

Phytoestrogens are non-steroidal plant-derived substances that show remote structural and definite functional similarities to estradiol. Beside the lignans, the isoflavones represent the main class of phytoestrogens. In contrast to less investigated other groups of phytoestrogens, e.g. coumestans and stil-benes, which in a lower amount are contained in food, isofla-vones are well studied. The most important representatives of this phytoestrogen class are genistein, daidzein, and glycitein. Their chemical structure consists of 2 phenolic rings that enable these substances to bind the estrogen receptor (ER) (fig. (fig.1).1). The estrogenic potency of isoflavones is about 100-fold (coumestrol) to 1,000-fold (daidzein) weaker than that of 17β-estradiol [6, 7]. But compared with 17β-estradiol peak levels in premenopausal women, the serum levels of isoflavones after dietary intake can be higher in the same manner. In contrast to 17β-estradiol, isoflavones prefer to bind to estrogen receptor β (ERβ), which partially explains their different effects [8]. Depending on ambient estrogen concentrations, isoflavones may exert their effects as estrogen antagonists in a high estrogen environment, or they may act as estrogen agonists in a low estrogen environment [9,10,11]. Therefore, isoflavones are also referred to as selective ER modulators (SERMs) [12, 13]. Furthermore, isoflavones show several non-hormonal effects such as inhibition of aromatase activity [14, 15], downregulation of protein tyrosine kinases (PTK) [16], or promoter methylation with modulation of gene expression [17]. However, the relevance of these effects still remains unclear.

Fig. 1
Chemical structures of estrogens and isoflavones indicating the similarities between both substance classes.

Unfortunately, the results of many studies are inconsistent due to a lot of bias [18, 19]. So far, there is low evidence for any well-defined estrogen-like or anti-estrogen-like effect in humans [20, 21]. One possible reason for the apparently incoherent findings could be the quantitatively and qualitatively variable composition of phytoestrogens in food stuff and their complex metabolism with the synthesis of miscellaneous derivates which partially show diverse biologic activities. Isofla-vones are contained in plants as glycosidic conjugates. After consumption, they are hydrolyzed by intestinal bacteria forming aglycons. The aglycons are metabolized in the intestinal wall and in the liver, and become glucoronide conjugates. Further metabolism to substances with different estrogenic potency is possible (e.g. equol, O-desmethylangolensin, p-ethyl-phenol). Last but not least, there is a big variability regarding the inter- and intra-individual metabolism - depending on differences in gut microflora (use of antibiotics!), genetic polymorphisms, or intestinal transit time [22, 23]. For example, the daidzein metabolite equol has been found in urine samples of only 20-30% of Japanese women, and depends also on dairy product intake [24].

The main natural dietary source of isoflavones are soy products which in Asian countries are traditionally consumed in high doses. With the exception of soy milk and soy infant formulas, isoflavone concentrations in soy products are comparatively high (0.5-3.0 mg/g). Soy products are followed by other legumes, particularly runner beans (Phaseolus coccineus) and mung beans (Vigna radiata), as well as flaxseed (Linum usi-tatissimum). But concentrations in these products are about 100-fold to 1,000-fold lower than in soy products [25]. However, the isoflavone levels of soy food differ considerably among the various preparations with high content in soy flour and powder and lower content in processed soy food like tofu or miso (fig. (fig.2).2). Boiling can decrease the isoflavone content of soybeans by more than half, but aglycons, which are found in high concentrations in fermented soy products like miso, are very stable at high temperature [25, 26].

Fig. 2
Total isoflavone concentrations (μg/g) of fermented and unfer-mented soy products. Relatively higher content of aglycons in the fermented soy products tempeh, bean paste, and miso [81].

The daily phytoestrogen intake is about 20-50 mg per person in East and Southeast Asian countries and is less than 1 mg in European countries and in the USA [27,28,29,30,31,32]. Interestingly, doughnuts constitute approximately 20% of the average daily intake of genistein and 15% of daidzein due to the high content of added soy flour in the USA [33].

High Isoflavone Consumption and Breast Cancer Risk

Given the great difference in soy consumption among Western versus Asian populations, these 2 groups should be examined separately. The first report of a breast cancer-preventive effect of a high phytoestrogen intake was published in 1991 for a population of Chinese women [34]. The meta-analysis of Wu et al. [35] gives a comprehensive overview on recent study findings (table (table1).1). It included 8 (1 cohort, 7 case-control) studies with almost complete assessment of the total soy intake in Asian or in Asian-American populations. A further 6 studies were excluded because of incomplete assessment of dietary soy intake. The analysis shows a statistically significant risk reduction of breast cancer by 29% for Asian women with continuous high soy intake (odds ratio (OR) = 0.71, 95% CI = 0.6-0.85). Cut off point for high intake was 20 mg soy isoflavones or more per day, lowest intake was 5 mg or less. Also, a moderate consumption of 10 mg per day showed a statistically significant risk reduction of 12% (OR = 0.88, 95% CI = 0.78-0.98). The described significant inverse correlation was observed in both pre- and postmenopausal women [35]. A large prospective cohort study including a total of 35,303 Singapore Chinese women confirmed the previous data. High soy intake (> 10.6 mg isoflavone/1,000 kcal) was associated with a significant breast cancer risk reduction compared with lower daily intake of soy products (risk ratio (RR) = 0.82, 95% CI = 0.70-0.97). The level of significance was reached only in a subgroup analysis of postmenopausal women, and amongst them the ones above the median body mass index (BMI > 24 kg/m2) (RR = 0.67, 95% CI = 0.51-0.88) were even more significant [36].

Table 1
Isoflavone intake and breast cancer risk in high-consuming populations

In a recent Japanese study (nested case-control within a prospective cohort of 24,226 women), high serum levels of genistein were statistically significantly inversely correlated to breast cancer risk in comparison to low serum levels (OR = 0.34, 95% CI = 0.16-0.74, p < 0.01). However, the medium isoflavone intake was 32.5 mg/day in the patient group and 32.1 mg/day in the control group. Therefore, the study did not find a statistically significant difference between isoflavone intake and breast cancer risk (p = 0.36). Furthermore, the authors assumed a threshold level of isoflavone effect due to the lack of data on a dose-response relationship. Unlike genistein, the second main isoflavone, daidzein, did not show any beneficial effect on breast cancer risk reduction (OR = 0.71, 95% CI = 0.35-1.44, p = 0.34). None of the findings were substantially influenced by potential confounders such as menopausal status or BMI. Although the study was well arranged, attention should be paid to the short half-live of isoflavones in the blood (only 6-8 h). To minimize the attenuation of risk estimates derived from random measurement errors, the authors matched fasting time between cases and controls [37]. In addition, another recently published Chinese case-control study showed a significant breast cancer risk reduction in women with high plasma levels of genistein (OR 0.26, 95% CI 0.13-0.50) [38].

Low Isoflavone Consumption and Breast Cancer Risk

The meta-analysis of Wu et al. [35] conducted in low-soy-consuming Western populations included 11 studies (table (table2).2). Four of them were cohort or nested case-control studies, and 7 were simple case-control studies. Combined (OR = 1.04, 95% CI = 0.97-1.11) as well as separate testing of cohort (OR 1.08, 95% CI = 0.95-1.24) and case-control studies (OR = 1.02, 95% CI = 0.95-1.11) revealed no significant differences between low (0.15 mg or less) and high (0.8 mg or more) daily isoflavone intake and breast cancer risk. There were no differences in results by menopausal status [35]. The results of the recently published studies are consistent with previous studies. Neither a large prospective US American cohort study (Iowa Women's Health Study, only postmenopausal women) nor 2 equally large prospective European cohort studies (pre- and postmenopausal women), all based on food frequency questionnaires (FFQ), presented any statistically significant effects on breast cancer risk by isoflavone intake [39,40,41]. In one case-control study, a significant increase of risk for breast cancer in relation to higher isoflavone intake was observed (OR = 1.08, 95% CI = 1.00-1.16, p = 0.055) [42]. In this study, isoflavone consumption was indirectly estimated by measurement of excreted substances in urine samples of pre- and postmenopausal women. The significance level was reached in the total isoflavone group, and further in a subgroup analysis of ER-positive breast cancers for equol - a rather strong estrogenic metabolite of daidzein (OR = 1.07, 95% CI = 1.01-1.12, p = 0.013). The increase in breast cancer risk was only marginal, and furthermore the values of urine samples are inconsistent with the values of the isoflavone plasma levels. Even the authors of this study did not dismiss the possibility of a false-positive finding as a result of the conducted multiple subgroup analyses. In contrast thereto are the results of a big Dutch nested case-control study of pre- and postmenopausal women and measurement of plasma levels of isoflavones [43]. Except genistein, all isoflavones showed a non-significant reduction in breast cancer risk. Comparing the highest versus the lowest tertile of plasma levels, genistein was associated with a significant decrease in overall breast cancer risk (OR = 0.68, 95% CI = 0.47-0.98, p = 0.07). A subgroup analysis revealed that the protective effect was much stronger in post- than in premenopausal women (OR = 0.76, 95% CI 0.45-1.09, p = 0.09 vs. OR = 0.67, 95% CI = 0.29-1.56, p = 0.30). Although women of European or US American descent show much lower circulating levels of isoflavones than Asian women, the endogenous levels of phytoetrogens are 50-1,000 times higher than endogenous estrogen levels in postmeno-pausal women. Given this, the authors concluded that biological effects of isoflavones may occur also in low-soy-consuming populations.

Table 2
Isoflavone intake and breast cancer risk in low-consuming populations

Isoflavones and Markers of Breast Cancer Risk

Assuming that estrogenic effects on breast tissue may indirectly estimate the risk of breast cancer development, some studies analyzed the impact of isoflavones on surrogate markers like mammographic density, measurement of the proliferation marker Ki-67 in breast tissue, and others [44, 45]. Several trials did not show any significant increase in breast tissue proliferation after treatment with isoflavones compared to placebo in both premenopausal and postmenopau-sal women. Doses of daily isoflavone intake ranged from 36 mg to 120 mg and duration of exposition from 14 days to 12 weeks [46,47,48]. Also, in accordance with the results on cell proliferation, the trials did not reveal a significant increase of mammographic breast density depending on isoflavone intake. Dietary daily isoflavone intake differed between 40 mg and 99 mg and study duration between 6 months and 3 years [49,50,51,52,53].

Isoflavones and Risk of Breast Cancer Recurrence

Most concerns regarding phytoestrogen intake after diagnosis of breast cancer are based on cell culture and animal studies which showed that phytoestrogens have growth stimulatory effects on human breast cancer cells (e.g. MCF-7) and on breast cancer xenoplants in athymic ovariectomized mice [54]. The induction of tumor growth by genistein is stronger than by daidzein. Surprisingly, the estrogenic metabolite equol did not enhance proliferation of breast cancer cells in the mouse model [54,55,56,57]. This means that phytoestrogens have a preventive effect on breast cancer development but have also stimulatory effects on the growth of ER-positive tumors in animal models and in cell culture. What could be the explanation for such divergent results? It may be hypothesized that both the cell culture system and the mouse model lack an endogenous estrogen environment. As a consequence, the low estrogen effect of isoflavones may stimulate tumor development. A milieu of higher endogenous estrogen may cause competition between isoflavones and estradiol for receptor binding sites and so the weaker estrogenic potency of isoflavones as well as the different binding preferences to the ERs α and β might lead to an anti-estrogenic effect. In a higher estrogen milieu isoflavonoids act in vitro as anti-estrogens, while in a low estrogen environment they act as estrogens as is characteristic for a postmenopausal situation [10]. In agreement, a more physiological mouse model with postmenopausal estrogen levels demonstrated an additional proliferative effect of genistein [58]. However, the addition of 17β-estradiol in only low postmenopausal levels of 20 pmol/l induced anti-proliferative effects on MCF-7 cells by isoflavonoids [59]. Furthermore, the injection of murine or human ER-negative breast carcinoma cells into soy-fed BALB/c mice resulted in reduced metastasis and tumor growth [60, 61].

The data currently available on the recurrence risk of breast cancer in women are sparse. Two population-based cohort studies examined the influence of soy intake and isoflavone intake, respectively. Boyapati et al. [62] analyzed the disease-free survival (DFS) of a group of 1,459 breast cancer patients taken from the Shanghai Breast Cancer Study cohort. The median time of follow-up was 5.2 years. The study did not observe any statistically significant association with overall survival between total isoflavone intake and DFS (third tertile vs. first tertile of isoflavone intake: hazard ratio (HR) = 1.06, 95% CI = 0.79-1.42, p = 0.64). Also, the subgroup analysis did not reveal any significant difference with respect to hormone receptor status, BMI, or menopausal status. Unfortunately, no data on tamoxifen use were taken. The second study was conducted on 1,210 breast cancer patients from the Long Island Breast Cancer Study Project. The patients were instructed to complete a FFQ when diagnosed with cancer. The follow-up time was 5 years. For the estimated adjusted HR for the highest isoflavone intake (> 7.48 mg/day) compared with the lowest one (< 0.29 mg/day), there was a trend towards a reduced risk but without statistical significance among both premeno-pausal and postmenopausal women for the all-cause mortality (HR = 0.52, 95% CI = 0.33-0.82, p = 0.37). Although the trend was more evident within the postmenopausal group, it was not significant either (HR = 0.44, 95% CI = 0.24-0.81, p = 0.34). The HRs for breast cancer-specific mortality did show a similar trend but with lower risk reduction. The subgroup analysis for hormone receptor status did not reveal any significant difference [63]. Neither study assessed possible postdiagnostic changes of isoflavone consumption.

Isoflavones and Antihormonal Treatment

The possible functional interaction of isoflavones with antihormonal therapy appears to be rather obscure. The estro-genic properties of isoflavones may possibly antagonize the anti-estrogenic action of tamoxifen. After xenotransplantion of a tamoxifen-sensitive human breast cancer cell line (MCF-7) in BALB/c nude mice, genistein reduced the growth inhibitory effect of tamoxifen [64]. In vitro cell cultures for daidzein proved the same. Only high and non-physiological concentrations of isoflavones inhibited tumor cell proliferation [65]. In contrast, Mai et al. [66] demonstrated synergistic effects of isoflavones (e.g. genistein) and tamoxifen on MCF-7 cells. Furthermore, genistein, in the presence of tamoxifen, exerted a synergistic influence on a hormone receptor positive, HER2-overexpressing human breast cancer cell line - a receptor combination with frequently encountered tamoxifen resistance [67]. Here, genistein decreased epithelial growth factor receptor (EGFR), HER2, and ERa expression. The authors assumed a potential therapeutic use in ER+/HER2+ breast cancer cases with tamoxifen resistance, where genistein could potentially reconstitute tamoxifen sensitivity. No influence on serum levels of tamoxifen and its metabolism was observed in female tamoxifen users [68]. Also, the activity of aromatase inhibitors (AI) seems to be influenced by isoflavones. Genistein abolished in the MCF-7 implanted BALB/c mouse model the growth inhibitory effect of the AI letrozole [69].

Given this, the effects of isoflavones on breast cancer survival are presently not clear. Adverse effects, particularly on hormone receptor-dependent breast cancer and on antihormonal therapies, cannot definitely be excluded even though the 2 cohort studies with over 2,500 patients did not demonstrate any detrimental outcome. Considering the potentially negative effect on breast cancer outcome, the German breast cancer commission of the ‘Arbeitsgemeinschaft Gynäkologische Onkologie, AGO’ recommends avoiding high isoflavone intake in breast cancer patients independent of the hormone receptor status [70].

Interaction of Isoflavone Intake and Mammary Development

Three studies evaluated the role of isoflavone intake and time of exposure. In all of the 3 studies, intake of isoflavones during adolescence was associated with a reduction of breast cancer risk. Shu et al. [71] found a statistically significant risk reduction between lowest and highest quintile of soy intake in Chinese women of OR = 0.51, 95% CI = 0.40-0.65, p < 0.001 (case-control study with 1,459 breast cancer cases, FFQ for the time between the ages of 13 and 15 years). A case-control study conducted by Wu et al. [72] on 501 Asian-American women with breast cancer revealed similar results. The comparison between the group with a generally high intake of isoflavones during adolescence (between ages 12 and 18) and adult life and the generally low intake group showed a significant risk reduction of OR = 0.51, 95% CI = 0.36-0.78, p < 0.001. High intake in adults who had a low intake during adolescence did not reveal a significant risk reduction (OR = 0.93, 95% CI = 0.58-1.48). High isoflavone intake only during adolescence seems to reduce the breast cancer risk to a lower degree (OR = 0.77, 95% CI = 0.51-1.16). The third study on 3,024 Canadian breast cancer patients (case-control) showed that higher phytoestrogen intake during adolescence was associated with a reduced breast cancer risk (OR = 0.71, 95% CI = 0.62-0.82, p < 0.001) [73]. Also, intake of soy-based formula in the first year of live could have a preventive effect on breast cancer development in later life. A small Canadian case-control study on 728 women with 372 cases of breast cancer revealed a risk reduction for the soy formula-fed group of OR = 0.42 (only soy milk vs. only breast/cow's milk in the first 4 months). The effect is not significant (95% CI = 0.13-1.40) not least due to the small study population [74]. The protective impact of isoflavones, especially of genistein, on breast tissue during the prepubertal and pubertal period was confirmed by several animal studies on rats [75]. The underlying mechanisms of action are not yet clear, but prepubertal soy feeding of female rats generates a reduction in the number of terminal end buds (TEBs) and an increase in lobular differentiation. The human equivalent to the TEB is the terminal ductal lobular unit (TDLU) which is the morphologic origin of most breast cancer cases. The structural changes are accompanied by a functional maturation of the gland with reduction of the cancer-sensitive stem cell pool and molecular switch to a less cancer-sensitive phenotype, respectively. Effects are determined by genetic and epigenetic phenomena and result amongst others in an upregulation of the tumor suppressor genes BRCA1 and PTEN. Warri et al. [75] proposed that early soy exposure might have a similar protective effect on the breast as early pregnancy. The findings are in agreement with the recently postulated importance of the sensitive window of pubertal breast development on cancer genesis [76,77,78].

Discussion and Open Questions

Due to the inconsistency of the data, an interpretation of the various study findings is hardly possible. The findings did however repeatedly reveal the following 2 main differences: Firstly, there is a discrepancy in breast cancer prevention between Western and Asian populations, that cannot be explained only by different amounts of daily isoflavone intake. Secondly, there is an obvious discrepancy between the beneficial trend of using isoflavone for purposes of breast cancer prevention in human studies and the detrimental effects on breast cancer growth in cell culture or in mouse models. Besides methodical problems, the age period of isoflavone exposure may be relevant for the incoherence of the data, but at present many questions about isoflavone effects and particularly its safety have not yet been answered: What is the epi-demiologic evidence on isoflavones and breast cancer risk? Is there a dose-response relationship or a threshold level? What about high-risk situations (especially BRCA mutations)?

The positive effects of high isoflavone intake in Asian women have been demonstrated by a sufficient number of powerful studies. In populations with low isoflavone intake, data have not shown a clear preventive effect on breast cancer development, but also lack evidence of any adverse influence on breast cancer risk. In conclusion, isoflavones can presently be regarded as relatively safe, but the effect of high ‘Asian-like’ isoflavone intake on Western populations remains uncertain. Therefore, formulas with high doses of phytoestrogens should be avoided. Further studies should evaluate the role of phy-toestrogens on breast cancer survival.

Our current knowledge about the safety of isoflavones in cases of breast cancer is really rudimentary. Patients often ask for alternative treatment options like phytoestrogens, but presently we have only few human studies dealing with this problem and so we are not able to give any satisfactory answer. Further investigations have to consider not only the hormone receptor status, but also the HER2 expression and histological properties. Also, does the endogenous estrogen environment influence the effects of the isoflavones? What is the impact of other phytoestrogens such as lignans and flavones? - An interesting question because of its common presence in Western diet products like tomatoes, berries, citrus fruits and many other fruits, vegetables, and herbs. Recent studies reported a modest decrease in risk of breast cancer in relation to intake of some flavones (apigenin, lute-olin) [79, 80]. - What is the impact of different isoflavone metabolites and differences in metabolism? Which influence do non-estrogenic effects have (e.g. inhibition of tyrosine kinases, influence on enzymatic estrogen metabolism, epige-netic modulation)?

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. [PubMed]
2. Hanf V, Gonder U. Nutrition and primary prevention of breast cancer: foods, nutrients and breast cancer risk. Eur J Obstet Gynecol Reprod Biol. 2005;123:139–149. [PubMed]
3. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057–2071. [PubMed]
4. Khaodhiar L, Ricciotti HA, Li L, Pan W, Schickel M, Zhou J, Blackburn GL. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause. 2008;15:125–132. [PMC free article] [PubMed]
5. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas. 2007;58:249–258. [PubMed]
6. Korner W, Spengler P, Bolz U, Schuller W, Hanf V, Metzger JW. Substances with estrogenic activity in effluents of sewage treatment plants in southwestern Germany. 2. Biological analysis. Environ Toxicol Chem. 2001;20:2142–2151. [PubMed]
7. Korner W, Hanf V, Schuller W, Bartsch H, Zwirner M, Hagenmaier H. Validation and application of a rapid in vitro assay for assessing the estrogenic potency of halogenated phenolic chemicals. Chemosphere. 1998;37:2395–2407. [PubMed]
8. Morito K, Hirose T, Kinjo J, Hirakawa T, Okawa M, Nohara T, Ogawa S, Inoue S, Muramatsu M, Masa-mune Y. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull. 2001;24:351–356. [PubMed]
9. Morito K, Aomori T, Hirose T, Kinjo J, Hasegawa J, Ogawa S, Inoue S, Muramatsu M, Masamune Y. Interaction of phytoestrogens with estrogen receptors alpha and beta (II) Biol Pharm Bull. 2002;25:48–52. [PubMed]
10. Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, Hur HG, Han KO. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol. 2006;101:246–253. [PubMed]
11. De Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother. 2001;35:1118–1121. [PubMed]
12. Brzezinski A, Debi A. Phytoestrogens: the 'natural' selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol. 1999;85:47–51. [PubMed]
13. Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol. 2008;22:1032–1043. [PubMed]
14. Wang Y, Man GW, Chan FL, Chen S, Leung LK. The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. Br J Nutr. 2008;99:303–310. [PubMed]
15. Rice S, Whitehead SA. Phytoestrogens and breast cancer - promoters or protectors? Endocr Relat Cancer. 2006;13:995–1015. [PubMed]
16. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592–5595. [PubMed]
17. King-Batoon A, Leszczynska JM, Klein CB. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ Mol Mutagen. 2008;49:36–45. [PubMed]
18. Gerber B, Muller H, Reimer T, Krause A, Friese K. Nutrition and lifestyle factors on the risk of developing breast cancer. Breast Cancer Res Treat. 2003;79:265–276. [PubMed]
19. Gerber B, Scholz C, Reimer T, Briese V, Janni W. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat. 2006;95:199–209. [PubMed]
20. Edmunds KM, Holloway AC, Crankshaw DJ, Agarwal SK, Foster WG. The effects of dietary phytoestrogens on aromatase activity in human en-dometrial stromal cells. Reprod Nutr Dev. 2005;45:709–720. [PubMed]
21. Sammartino A, Di Carlo C, Mandato VD, Bifulco G, Di Stefano M, Nappi C. Effects of genistein on the endometrium: ultrasonographic evaluation. Gynecol Endocrinol. 2003;17:45–49. [PubMed]
22. Yu ZT, Yao W, Zhu WY. Isolation and identification of equol-producing bacterial strains from cultures of pig faeces. FEMS Microbiol Lett. 2008;282:73–80. [PubMed]
23. Halm BM, Franke AA, Ashburn LA, Hebshi SM, Wilkens LR. Oral antibiotics decrease urinary iso-flavonoid excretion in children after soy consumption. Nutr Cancer. 2008;60:14–22. [PubMed]
24. Nagata C, Ueno T, Uchiyama S, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H. Dietary and lifestyle correlates of urinary excretion status of equol in Japanese women. Nutr Cancer. 2008;60:49–54. [PubMed]
25. Liggins J, Bluck LJ, Runswick S, Atkinson C, Coward WA, Bingham SA. Daidzein and genistein contents of vegetables. Br J Nutr. 2000;84:717–725. [PubMed]
26. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr. 1998;68:1333S–1346S. [PubMed]
27. Chen Z, Zheng W, Custer LJ, Dai Q, Shu XO, Jin F, Franke AA. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer. 1999;33:82–87. [PubMed]
28. Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, Nakayama T, Wada M, Ohno Y. Dietary intake and sources of isoflavones among Japanese. Nutr Cancer. 1999;33:139–145. [PubMed]
29. Surh J, Kim MJ, Koh E, Kim YK, Kwon H. Estimated intakes of isoflavones and coumestrol in Korean population. Int J Food Sci Nutr. 2006;57:325–344. [PubMed]
30. Mulligan AA, Welch AA, McTaggart AA, Bhaniani A, Bingham SA. Intakes and sources of soya foods and isoflavones in a UK population cohort study (EPIC-Norfolk) Eur J Clin Nutr. 2007;61:248–254. [PubMed]
31. Boker LK, van der Schouw YT, De Kleijn MJ, Jacques PF, Grobbee DE, Peeters PH. Intake of dietary phytoestrogens by Dutch women. J Nutr. 2002;132:1319–1328. [PubMed]
32. De Kleijn MJ, van der Schouw YT, Wilson PW, Adlercreutz H, Mazur W, Grobbee DE, Jacques PF. Intake of dietary phytoestrogens is low in post-menopausal women in the United States: the Framingham study(1-4) J Nutr. 2001;131:1826–1832. [PubMed]
33. Horn-Ross PL, Lee M, John EM, Koo J. Sources of phytoestrogen exposure among non-Asian women in California, USA. Cancer Causes Control. 2000;11:299–302. [PubMed]
34. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast-cancer risk in Singapore. Lancet. 1991;337:1197–1200. [PubMed]
35. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 2008;98:9–14. [PMC free article] [PubMed]
36. Wu AH, Koh WP, Wang R, Lee HP, Yu MC. Soy intake and breast cancer risk in Singapore Chinese Health Study. Br J Cancer. 2008;99:196–200. [PMC free article] [PubMed]
37. Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Yamamoto S, Tsugane S. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol. 2008;26:1677–1683. [PubMed]
38. Lampe JW, Nishino Y, Ray RM, Wu C, Li W, Lin MG, Gao DL, Hu Y, Shannon J, Stalsberg H, Porter PL, Frankenfeld CL, Wahala K, Thomas DB. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2007;16:2579–2586. [PubMed]
39. Cutler GJ, Nettleton JA, Ross JA, Harnack LJ, Jacobs DR, Jr., Scrafford CG, Barraj LM, Mink PJ, Robien K. Dietary flavonoid intake and risk of cancer in postmenopausal women: the Iowa Women's Health Study. Int J Cancer. 2008;123:664–671. [PMC free article] [PubMed]
40. Hedelin M, Lof M, Olsson M, Adlercreutz H, Sandin S, Weiderpass E. Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast tumors in Swedish women. J Nutr. 2008;138:938–945. [PubMed]
41. Travis RC, Allen NE, Appleby PN, Spencer EA, Roddam AW, Key TJ. A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer. 2008;122:705–710. [PubMed]
42. Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study. Breast Cancer Res. 2008;10:R32. [PMC free article] [PubMed]
43. Verheus M, van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters PH. Plasma phytoes-trogens and subsequent breast cancer risk. J Clin Oncol. 2007;25:648–655. [PubMed]
44. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354:270–282. [PubMed]
45. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J. 2008;7:17. [PMC free article] [PubMed]
46. Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgren BM. Isoflavone treatment for acute men-opausal symptoms. Menopause. 2007;14:468–473. [PubMed]
47. Sartippour MR, Rao JY, Apple S, Wu D, Henning S, Wang H, Elashoff R, Rubio R, Heber D, Brooks MN. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr Cancer. 2004;49:59–65. [PubMed]
48. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A, Bundred NJ. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84:4017–4024. [PubMed]
49. Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, Affen J, Flook LA, Tidy A. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int. 2008;14:6–12. [PubMed]
50. Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE, Bingham SA. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165] Breast Cancer Res. 2004;6:R170–R179. [PMC free article] [PubMed]
51. Maskarinec G, Williams AE, Carlin L. Mammo-graphic densities in a one-year isoflavone intervention. Eur J Cancer Prev. 2003;12:165–169. [PubMed]
52. Verheus M, van Gils CH, Kreijkamp-Kaspers S, Kok L, Peeters PH, Grobbee DE, van der Schouw YT. Soy protein containing isoflavones and mam-mographic density in a randomized controlled trial in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17:2632–2638. [PubMed]
53. Kataoka M, Atkinson C, Warren R, Sala E, Day NE, Highnam R, Warsi I, Bingham SA. Mammo-graphic density using two computer-based methods in an isoflavone trial. Maturitas. 2008;59:350–357. [PubMed]
54. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998;58:3833–3838. [PubMed]
55. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001;61:5045–5050. [PubMed]
56. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr. 2001;131:2957–2962. [PubMed]
57. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis. 2006;27:856–863. [PubMed]
58. Ju YH, Allred KF, Allred CD, Helferich WG. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis. 2006;27:1292–1299. [PubMed]
59. Imhof M, Molzer S, Imhof M. Effects of soy isoflavones on 17beta-estradiol-induced proliferation of MCF-7 breast cancer cells. Toxicol In Vitro. 2008;22:1452–1460. [PubMed]
60. Yan L, Li D, Yee JA. Dietary supplementation with isolated soy protein reduces metastasis of mammary carcinoma cells in mice. Clin Exp Metastasis. 2002;19:535–540. [PubMed]
61. Kim HA, Jeong KS, Kim YK. Soy extract is more potent than genistein on tumor growth inhibition. Anticancer Res. 2008;28:2837–2841. [PubMed]
62. Boyapati SM, Shu XO, Ruan ZX, Dai Q, Cai Q, Gao YT, Zheng W. Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study. Breast Cancer Res Treat. 2005;92:11–17. [PubMed]
63. Fink BN, Steck SE, Wolff MS, Britton JA, Kabat GC, Gaudet MM, Abrahamson PE, Bell P, Schroeder JC, Teitelbaum SL, Neugut AI, Gammon MD. Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol Biomarkers Prev. 2007;16:2285–2292. [PubMed]
64. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002;62:2474–2477. [PubMed]
65. Limer JL, Parkes AT, Speirs V. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J Cancer. 2006;119:515–521. [PubMed]
66. Mai Z, Blackburn GL, Zhou JR. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis. 2007;28:1217–1223. [PMC free article] [PubMed]
67. Mai Z, Blackburn GL, Zhou JR. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog. 2007;46:534–542. [PMC free article] [PubMed]
68. Wu AH, Pike MC, Williams LD, Spicer D, Tseng CC, Churchwell MI, Doerge DR. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin Oncol. 2007;25:3024–3030. [PubMed]
69. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis. 2008;29:2162–2168. [PMC free article] [PubMed]
70. Hanf V: Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer: Complementary Therapy and Hormonal Treatment in Breast Cancer Survivors and (Plant) Alternatives and Survivorship. g_mamma_08_1_1_c_25_complementary_therapy_hrt_survivorship.pdf Version 2008; Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma.
71. Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, Ruan Z, Gao YT, Zheng W. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev. 2001;10:483–488. [PubMed]
72. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis. 2002;23:1491–1496. [PubMed]
73. Thanos J, Cotterchio M, Boucher BA, Kreiger N, Thompson LU. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada) Cancer Causes Control. 2006;17:1253–1261. [PubMed]
74. Boucher BA, Cotterchio M, Kreiger N, Thompson LU. Soy formula and breast cancer risk. Epidemiology. 2008;19:165–166. [PubMed]
75. Warri A, Saarinen NM, Makela S, Hilakivi-Clarke L. The role of early life genistein exposures in modifying breast cancer risk. Br J Cancer. 2008;98:1485–1493. [PMC free article] [PubMed]
76. Russo J, Mailo D, Hu YF, Balogh G, Sheriff F, Russo IH. Breast differentiation and its implication in cancer prevention. Clin Cancer Res. 2005;11:931s–936s. [PubMed]
77. Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely OM, O'Malley BW, Medina D. Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis. 1998;19:1573–1581. [PubMed]
78. Hilakivi-Clarke L. Nutritional modulation of terminal end buds: its relevance to breast cancer prevention. Curr Cancer Drug Targets. 2007;7:465–474. [PubMed]
79. Gammon MD, Fink BN, Steck SE, Wolff MS. Soy intake and breast cancer: elucidation of an unanswered question. Br J Cancer. 2008;98:2–3. [PMC free article] [PubMed]
80. Bosetti C, Spertini L, Parpinel M, Gnagnarella P, Lagiou P, Negri E, Franceschi S, Montella M, Peterson J, Dwyer J, Giacosa A, La Vecchia C. Flavonoids and breast cancer risk in Italy. Cancer Epidemiol Biomarkers Prev. 2005;14:805–808. [PubMed]
81. Wang H, Murphy PA. Isoflavone Content in Commercial Soybean Foods. J Agric Food Chem. 1994;42:1666–1673.

Articles from Breast Care are provided here courtesy of Karger Publishers